Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz235/30139891/mdz235.pdf
Reference94 articles.
1. Alpelisib for PIK3CA mutated, hormone-receptor positive breast cancer;Andre;N Engl J Med,2019
2. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer;Andre;N Engl J Med,2019
3. Overall survival with palbociclib and fulvestrant in advanced breast cancer;Turner;N Engl J Med,2018
4. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial;Tripathy;Lancet Oncol,2018
5. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer;Goetz;J Clin Oncol,2017
Cited by 500 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A tumor microenvironment-activated near-infrared photosensitizer enable efficient photodynamic therapy of breast tumor;Sensors and Actuators B: Chemical;2024-11
2. Long‐term outcomes and risk profile of cT3N0 breast cancer treated with neoadjuvant chemotherapy and curative surgery;Journal of Medical Imaging and Radiation Oncology;2024-09-09
3. Mass Spectrometry-Based Proteomics for Classification and Treatment Optimisation of Triple Negative Breast Cancer;Journal of Personalized Medicine;2024-09-05
4. Insights Into Benzothiazolyl‐Coupled Azetidinone Moieties Toward EGFR Binding and Stability Analysis—Evidence From Molecular Docking and Dynamics Simulation;Peptide Science;2024-08-28
5. Selective Estrogen Receptor Modulators’ (SERMs) Influence on TET3 Expression in Breast Cancer Cell Lines with Distinct Biological Subtypes;International Journal of Molecular Sciences;2024-08-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3